Theracryf PLC Regulatory News (TCF)

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Total Voting Rights

Alderley Park, UK - 2 May 2024:  In accordance with Disclosure Guidance and Transparency Rule 5.6.1, the Company would like to notify the market that as of 30 April 2024, the total number of Ordinary Shares in issue is 427,346,895, with no shares held in treasury. This is the figure that may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

- Ends -

Enquiries

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications such as neurodevelopmental disorders, glioblastoma*, addiction, anxiety and narcolepsy* [*orphan indications]. Its strategy is to generate compelling data sets to proof of concept and/or later phase II to partner its clinical programmes with mid-size to large pharma. As well as a number of industry partnerships with companies, including Stalicla, in neurodevelopment disorders and has sourced programmes from companies such as Takeda and Shire, the Company has worked with and has ongoing collaborations with major universities, hospitals and government organisations such as the University of Manchester, Sapienza (Università di Roma), Kings College London and University of Connecticut.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol TCF. 

For further information, please visit: www.theracryf.com